氘可来昔替尼和阿普司特哪个好

Deuterated colexitinib is the world's first approved TYK2 inhibitor. For the treatment of psoriasis, TYK2 is a more precise and safer target than other JAKs. Deuterated colexitinib has many advantages such as rapid absorption, good efficacy, and high safety. It is suitable for the treatment of moderate to severe plaque psoriasis in adults. Patients require systemic treatment or phototherapy.

A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study (POETYK PSO-3) showed that 62.9% of patients with moderate to severe scalp psoriasis achieved ss-PGA after 16 weeks of continuous treatment with deuterated colexitinib. 0/1 (scalp skin lesions are cleared or basically cleared), which is better than the placebo group (9.8%), which means that deuterated coxitinib also shows significant benefit in clearing skin lesions in refractory areas (scalp).

Apremilast is indicated for the treatment of adults with moderate to severe plaque psoriasis (Psoriasis) who are candidates for phototherapy and systemic therapy, and is also indicated for the treatment of adults with active psoriatic arthritis (PsA). Apremilast, a PDE4 inhibitor specific for cyclic adenosine monophosphate (cAMP), reduces erythema, thickening, and scaling in patients with moderate to severe plaque psoriasis.

Apremilast's inhibitory effect on PDE4 results in increased intracellular cAMP levels, which may suppress immune and inflammatory responses. Apremilast mechanistically relieves psoriasis inflammation and improves comorbidities of psoriasis. It can fully meet the treatment needs of psoriasis patients. It has good therapeutic effect and tolerability, oral administration, and new action targets.

Which is better, deuterated coxitinib or apremilast?

Trials have shown that Apremilast is slightly better than Apremilast in improving psoriasis, but Apremilast is a second- and third-line drug for psoriasis combined with psoriatic arthritis, inflammatory bowel disease, and cardiovascular disease. It has a wider range of applications than deuterated colexitinib. The patients' conditions are different, and the drugs and treatment plans they choose are also different. Whether to use deuterated coxitinib or apremilast, it is recommended that patients choose under the guidance of a doctor and receive symptomatic treatment.

Recommended related articles: